ClinicalTrials.gg
Active, not recruitingNCT03070366OMETUpdated Oct 2, 2026

Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

A Phase 2 interventional study of Chemotherapy and Stereotactic radiotherapy in Head and Neck Squamous Cell Carcinoma, sponsored by Groupe Oncologie Radiotherapie Tete et Cou. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Groupe Oncologie Radiotherapie Tete et Cou · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Sep 2015, registered Jan 2017).
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Squamous Cell Carcinoma of Head and Neck by Groupe Oncologie Radiotherapie Tete et Cou — 3 open to participants now, 8 under way, 5 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Groupe Oncologie Radiotherapie Tete et Cou.

Planned enrollment
16th of 21
78 · median 133
Started
2015
with 2 others
Phase 2
10 of 22
2 open now
Registered
15th of 22
by date

Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by Groupe Oncologie Radiotherapie Tete et Cou, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2015, is one of 10 in phase 2, and was the 15th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by Groupe Oncologie Radiotherapie Tete et Cou are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Squamous Cell Carcinoma of Head and Neck by Groupe Oncologie Radiotherapie Tete et Cou, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the rate of living patients at 1 year with a quality of life criteria (no decrease) and reduced toxicities. This criteria will be compared in both groups., A cost effectiveness study is scheduled also.

Read the detailed description

Patients with cancers of aerodigestive tract have metastases limited in their evolution and a pauci-metastatic disease. In these cases, systemic therapy is the standard attitude. However, patients often received chemotherapy in their history and response rates are relatively low. The median survival is between 7 and 11 months with secondary effects and degradation of quality of life. It is a palliative treatment. Data on systemic treatment in the context of a micro-metastatic disease are limited. In contrast, stereotactic irradiation in pauci-metastatic context leads to better local control rates and may sustainedly reduce the progression of metastatic disease.

Stereotactic radiotherapy is increasing use in clinical practice for limited metastatic stages (oligo metastatic with 1-3 synchronized metastases). Radiotherapy in this indication has major advantages and a similar efficacy compared with other ablative treatments.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Oligometastasis
  • stereotactic irradiation
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • PS:0-2
  • Estimated ≥ 6 months
  • confirmed diagnosis of squamous cell carcinoma of the head and neck
  • Target can be treated in stereotactic radiotherapy
  • 1-3 synchronized metastases with unrestricted anatomic site
  • Greater cumulative diameter of synchronous metastases in once organ (liver, lung or brain) ≤ 6 cm with GTV = Clinical Target Volume (CTV)
  • Global maximum diameter (GTV) allowed for pulmonary oligometastases (less than 2 cm from the mediastinum), brain, node, is ≤ 3cm
  • Implementation of a method for taking into account movements and uncertainties (IGRT) for limiting the margin of CTV to PTV (PTV) so as not to exceed 7 cm large cumulative diameter of PTV
  • Performing a positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (FDG-PET) 4 weeks before the inclusion
  • In case of cerebral metastases, MRI diagnostic is required
  • If locoregional disease is treated, controlled and non-progressive for more than three months (+/- 4 weeks) at baseline, synchronized initial tumor is possible
  • If metachronous metastases, locoregional disease previously treated should be monitored and considered not progressive for more than three months at baseline
  • In case of prior cancer other than HNSCC, complete remission for over 5 years is possible, any of metastases is left to the appreciation of referring physician
  • No chemotherapy or local treatment of metastases in the previous 6 months
  • Laboratory tests consistent with the achievement of chemotherapy: Leukocytes> 3,000 / mm3 (including polynuclear> 2000 / mm3) > 150,000 / mm3, serum glutamate oxaloacetate transminase (), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase, \<2.5 (ULN)
  • Affiliation to an health insurance
  • Form signed

Exclusion criteria

Exclusion Criteria:

  • Concomitant participation in other interventional clinical trial within 4 weeks before inclusion
  • Other prior ablative treatment of targets (surgery, radio frequency) in the previous six months
  • metachronous primitive tumor (second cancer) uncontrolled.
  • to any systemic therapy (chemotherapy and / or targeted therapy)
  • Known reaction to 5FU, cisplatin, carboplatin, platin or cetuximab
  • Active infection (infection requiring IV antibiotics), including active tuberculosis and known and declared (HIV)
  • Other within 5 years prior to randomization, with the exception of adequately treated basal skin cancer and carcinoma in situ of the cervix
  • Individual deprived of liberty by judicial or administrative decision, or under any kind of guardianship
  • Pregnant or breast feeding women. Every woman who has , must have a negative pregnancy test (serum or urine) within 14 days previous treatment. Patients (men or women) must use a reliable method of throughout treatment and for at least 6 months after discontinuation of chemotherapy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Chemotherapy combined with stereotactic radiotherapy (RT)

    Chemotherapy is based on patient Performance Status (PS) and comorbidities: * PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion) * PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks). Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation. Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity.

    Drug: Chemotherapy · Radiation: Stereotactic radiotherapy

  • Experimental
    stereotactic radiotherapy

    Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.

    Radiation: Stereotactic radiotherapy

Interventions

  • DrugChemotherapy

    * cisplatin * 5FU * carboplatin * cetuximab

  • RadiationStereotactic radiotherapy

    Stereotactic radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival without quality of life deterioration

    Overall Survival rate without definitive deterioration of quality of life (by QLQC30) measured at 1 year post treatment

    Time frame: 1 year

Secondary outcomes

  1. Overall Survival

    Time frame: 1 year

  2. Progression free survival

    Time frame: through study completion, an average of 1 year

  3. Number of participants with adverse events grade 3 as assessed by CTCAE v4.0 within the first 6 months of treatment

    Toxicity of grade \> or equal to 3, occurring within the first 6 months of treatment

    Time frame: up to 6 months

  4. Number of participants with treatment related adverse events as assessed by CTCAE v4.0

    Time frame: through study completion, an average of 1 year

  5. Overall response rate

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The Data Monitoring Committee will meet every year either by a physical meeting or by conference call. Data on the recruitment, toxicity and autonomy are submitted every year.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Dec 2026, 135 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 135 months is above that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jul 2026 → Dec 2026 and completion Jul 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2017
First posted
Mar 3, 2017
StartActual
Sep 21, 2015
Primary completionEst.
Dec 2026was Jul 2026
CompletionEst.
Dec 2026was Jul 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Dec 2026
Oct 2, 2026
Study completion
Jul 2026→Dec 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Jul 2026→Dec 2026
    Study completion Jul 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03070366
Lead sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
Sep 21, 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion